Short interest for healthcare stocks in S&P 500 rose slightly in January vs. December, while Moderna continued to be the most ...

Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...

Moderna Inc.’s stock fell 2.9% early Friday, after the biotech posted a wider-than-expected fourth-quarter loss and offered ...

Moderna shares recovered from an early dip premarket despite the biotech's quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2 ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Wilmington Savings Fund Society FSB grew its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 295.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 786 shares of the ...

Inflation data, Powell testimony, more earnings will be in focus this week. • Robinhood’s strong financial health, robust ...

格隆汇2月14日｜医药企业Moderna表示，因安全顾虑，美国食品药品监督管理局 (FDA)暂停了其诺如病毒疫苗试验。莫德纳预计，FDA的暂停决定对其诺如病毒试验的影响甚微。

Shares of Moderna, along with other vaccine makers, dropped further this year as lawmakers advanced President Donald Trump's ...

Looking ahead, BofA cut its 2025 and 2026 revenue forecasts by 18% and 15%, respectively. While negative EPS projections ...